Tripadvisor, Inc. (NASDAQ:TRIP) announced on November 5, 2026, that CEO and Board member Matt Goldberg will depart the company, and that CFO Michael Noonan separately plans to resign, triggering an interim leadership arrangement effective January 1, 2027.
Wheels Up Experience Inc. filed a Form 8-K on November 5, 2026, disclosing that on November 4, 2026 the company entered into Amendment No. 6 to its existing Credit Agreement to add a $100.0 million revolving credit facility provided by Delta Air Lines, and …
Peloton Interactive, Inc. filed a Form 8-K with the SEC on November 5, 2026, announcing financial results for the quarter ended September 30, 2026, alongside a conference call and press release on the same date.
Precision BioSciences, Inc. filed a Form 8-K with the SEC on November 5, 2026, disclosing clinical trial updates for its PBGENE-HBV and PBGENE-DMD programs, including the advancement of the ELIMINATE-B study to Phase 2 and an eight-week safety observation for the first FUNCTION-DMD patient.
Genprex, Inc. filed a Form 8-K on November 5, 2026, disclosing a press release announcing translational analysis results from patients treated with its lead drug candidate, Reqorsa (quaratusugene ozeplasmid), presented at the Gerontological Society of America 2026 Annual Scientific Meeting.
Teleflex Incorporated filed an 8-K current report on November 5, 2026, announcing financial results for the quarter ended September 30, 2026, via a press release and an accompanying earnings conference call slide presentation.
N-able, Inc. filed a Form 8-K with the SEC on November 5, 2026, reporting the issuance of a press release covering its financial results for the third quarter ended September 30, 2026.
Frontdoor, Inc. filed a Current Report on Form 8-K on November 5, 2026, announcing the availability of its financial results for the fiscal quarter ended September 30, 2026, via an attached press release.
Shake Shack Inc. filed a Form 8-K with the SEC on November 5, 2026, announcing the release of its financial results for the fiscal third quarter ended September 30, 2026, via a press release and shareholder letter.
Korro Bio, Inc. filed a Form 8-K on November 5, 2026, disclosing that Novo Nordisk A/S issued written notice on November 3, 2026, to terminate for convenience its research collaboration and license agreement with Korro Bio, with the termination effective February 1, 2027.